| Foreword to the First Edition | xiii |
| Introduction to the First Edition | xv |
| Introduction to the Second Edition | xxi |
Section I | Scientific Rationale | |
Chapter 1 | Scientific Rationale for EDTA Chelation Therapy in Treatment of Atherosclerosis and Diseases of Aging | 3 |
Chapter 2 | Iron and Ischemic Heart Disease | 62 |
Chapter 3 | The Crosslinkage Theory of Aging As a Predictive Indicator | 67 |
Chapter 4 | Possibilities and Limitations of Chelation As a Means for Life Extension | 88 |
Chapter 5 | Nutritional Factors in Cardiovascular Disease | 100 |
Section II | Clinical Trials | |
Chapter 6 | Current Status of EDTA Chelation Therapy in Occlusive Arterial Disease | 120 |
Chapter 7 | EDTA Chelation Therapy: Efficacy in Arteriosclerotic Heart Disease | 133 |
Chapter 8 | EDTA Chelation Therapy: Efficacy in Brain Disorders | 142 |
Chapter 9 | An Oculocerebrovasculometric Analysis of the Improvement in Arterial Stenosis following EDTA Chelation Therapy | 164 |
Chapter 10 | Effect of EDTA Chelation Therapy plus Multivitamin-Trace Mineral Supplementation upon Vascular Dynamics: Ankle/Brachial Doppler Systolic Blood Pressure Ratio | 168 |
Chapter 11 | Effect of EDTA Chelation Therapy: Treatment of Peripheral Arterial Occlusion, an Alternative to Amputation | 177 |
Chapter 12 | Ninety Percent Reduction in Cancer Mortality after Chelation Therapy with EDTA | 195 |
Chapter 13 | The "Clinical Change" in Patients Treated with EDTA Chelation plus Multivitamin/Trace Mineral Supplementation | 202 |
Chapter 14 | EDTA Chelation Therapy: A Retrospective Study of 2,870 Patients | 210 |
Chapter 15 | Benefits of EDTA Chelation Therapy on Arteriosclerosis: A Retrospective Study of 470 Patients | 225 |
Chapter 16 | Visual Field Evidence of Macular Degeneration Reversal Using a Combination of EDTA Chelation and Multiple Vitamin and Trace Mineral Therapy | 237 |
Chapter 17 | A Nonsurgical Approach to Obstructive Carotid Stenosis Using EDTA Chelation | 247 |
Chapter 18 | The Effect of Intravenous Disodium Ethylenediaminetetraacetic Acid (EDTA) upon Bone Density Levels | 259 |
Chapter 19 | Renal Artery Stenosis Reversal in a Hypertensive Individual, Using a Combination of EDTA Chelation and Multiple Vitamin and Trace Mineral Therapy | 265 |
Chapter 20 | The Effect of EDTA Chelation Therapy with Multivitamin/Trace Mineral Supplementation upon Reported Fatigue | 273 |
Chapter 21 | Clinical Improvements as Judged by the Cornell Medical Index Questionnaire in Patients Treated with EDTA Chelation Therapy | 278 |
Chapter 22 | A Pilot Double-Blind Study of Sodium-Magnesium EDTA in Peripheral Vascular Disease | 285 |
Chapter 23 | The Correlation between EDTA Chelation Therapy and Improvement in Cardiovascular Function: A Meta-Analysis | 294 |
Chapter 24 | EDTA Chelation Treatment for Vascular Disease: A Meta-Analysis Using Unpublished Data | 317 |
Chapter 25 | If EDTA Chelation Therapy Is So Good, Why Is It Not More Widely Accepted? | 329 |
Section III | Safety | |
Chapter 26 | Kidney Effects of Ethylene Diamine Tetraacetic Acid (EDTA): A Literature Review | 345 |
Chapter 27 | The Effect of EDTA Chelation Therapy plus Supportive Multivitamin-Trace Mineral Supplementation upon Renal Function: A Study in Serum Creatinine | 352 |
Chapter 28 | The Improvement in Renal Function following EDTA Chelation and Multivitamin-Trace Mineral Therapy: A Study in Creatinine Clearance | 361 |
Chapter 29 | The Effect of EDTA Chelation Therapy plus Supportive Multivitamin-Trace Mineral Supplementation upon Renal Function: A Study in Blood Urea Nitrogen (BUN) | 366 |
Chapter 30 | Another Look at Renal Function and the EDTA Chelation Treatment Process | 376 |
Section IV | History and Protocol for Administration | |
Chapter 31 | Overview, Historical Background, and Current Status of EDTA Chelation Therapy for Atherosclerosis | 382 |
Chapter 32 | Protocol for the Safe and Effective Administration of EDTA and Other Chelating Agents for Vascular and Degenerative Diseases | 404 |
Chapter 33 | Iron and Copper Supplementation with EDTA Chelation Therapy | 462 |
Section V | Laboratory Evaluation | |
Chapter 34 | A Laboratory Method to Measure Plasma EDTA Levels | 468 |
Chapter 35 | Monitoring Renal Function during EDTA Chelation Therapy | 477 |
Chapter 36 | Urinary Trace and Toxic Elements and Minerals in Untimed Urine Specimens Relative to Urine Creatinine, Part I: Concentrations of Elements in Fasting Urine | 484 |
Chapter 37 | Urinary Trace and Toxic Elements and Minerals in Untimed Urine Specimens Relative to Urine Creatinine, Part II: Provoked Increase in Excretion following Intravenous EDTA | 503 |
Chapter 38 | Testing for Toxic Elements and Chelation of Mercury | 540 |
| Index | 549 |
| About Dr. Cranton | 565 |